AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin therapeutics, operating in the life sciences and specialty pharma sector. The company went public through a SPAC merger with Priveterra Acquisition Corp, sponsored by Priveterra LLC, which completed its IPO in 2021. On April 10, 2023, AEON filed a 10-K/A, an amendment to its annual report, with the SEC under CIK 0001837607. Following the business combination, AEON trades on the NYSE under the ticker AEON. The company's lead program, ABP-450 (prabotulinumtoxinA), targets therapeutic indications including cervical dystonia. For complete filing history, deal terms, and SPAC analytics on AEON Biopharma and hundreds of other transactions, sign up for full data access at SpacDesk.